Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01411774 · ClinicalTrials.gov registry record · Phase 3
D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)
A Phase 3 study, sponsored by University of South Florida.
- Completed
- Registry status
- Phase 3
- Development phase
- 142
- Enrollment target
NCT01411774: Completed Phase 3 study, sponsored by University of South Florida.
NCT01411774 is a Phase 3 study that has completed, run by University of South Florida. The registered enrollment target is 142 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01411774, a Phase 3 study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 142 participants
- Enrollment target
Study Summary
The investigators are conducting a randomized double-blind placebo-controlled study to assess the efficacy of d-cycloserine augmentation of cognitive-behavioral therapy for the treatment of pediatric obsessive compulsive disorder. This study represents an innovative approach in translating bench research findings into clinical research and testing a new approach for optimizing an effective psychotherapy with a safe non-psychotropic medication.
Primary Outcome
The Children's Yale-Brown Obsessive-Compulsive Scale measures the severity of OCD symptoms. There are 10 questions that are summed to arrive at a total score, with higher scores representing more severe OCD symptoms (scores range from 0-40).
Interventions
- DRUG d-cycloserine
- BEHAVIORAL Cognitive-behavioral therapy
- DRUG Pill placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2011-06 |
| Est. Completion | 2017-06 |
| Phase | Phase 3 |
What the finished NCT01411774 record still lists
NCT01411774 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 3 interventions - of which d-cycloserine is the first listed.
NCT01411774 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01411774 about?
NCT01411774 is a clinical study titled "D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)". The investigators are conducting a randomized double-blind placebo-controlled study to assess the efficacy of d-cycloserine augmentation of cognitive-behavioral therapy for the treatment of pediatric obsessive compulsive disorder. This study represents an innovative approach in translating bench res...
What is the current status of trial NCT01411774?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2011-06. Estimated completion is 2017-06.
What interventions are being tested in trial NCT01411774?
The interventions under investigation include: d-cycloserine (DRUG), Cognitive-behavioral therapy (BEHAVIORAL), Pill placebo (DRUG).
Who is sponsoring clinical trial NCT01411774?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01411774's enrollment target sits among peer trials
142 1559th of 2000 higher than 438 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia